Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 13/20 | 0.75 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.73 |
| ▸ | KIT | P10721 | 4/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.70 |
| ▸ | KDR | P35968 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | FLT3 | P36888 | 1/20 | 0.69 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4112245 | 0.86 | ABL1 (1.00) | ABL1KITFGFR1KDRCYP2C9 | |
| SCHEMBL13813533 | 0.85 | KIT (0.64) | ABL1KITKDR | |
| SCHEMBL22549164 | 0.85 | KIT (0.84) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL19317717 | 0.85 | ABL1 (0.84) | ABL1DDR1KITFGFR1KDR | |
| SCHEMBL24626458 | 0.85 | KIT (0.84) | ABL1KITFGFR1KDRCYP2C9 | |
| SCHEMBL21730540 | 0.85 | FGFR1 (0.85) | ABL1KITFGFR1KDRCYP2C9 | |
| SCHEMBL29675188 | 0.85 | KIT (0.84) | ABL1KITFGFR1KDRCYP2C9 | |
| SCHEMBL3432243 | 0.84 | DDR1 (1.00) | ABL1DDR1KITFGFR1KDR | |
| SCHEMBL31620735 | 0.84 | KIT (1.00) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL13765778 | 0.84 | KIT (1.00) | ABL1DDR1KITFGFR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005738-A1 | Monocyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8278307-B2 | Monocyclic Heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | CYP11B2, CYP3A5, CYP1A2 | ABL1 357/4885DDR1 4773/4885KIT 813/4885 |
| US-20130005738-A1 | Monocyclic Heteroaryl Compounds | CYP3A43, CYP2F1, CYP11B2 | ABL1 71/4885DDR1 4818/4885KIT 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.